Key facts: On 30 September 2025, GSK plc began a £0.3 billion share buyback, part of its £2 billion program, to return capital to shareholders and boost earnings per share.
Lesedauer weniger als 1 min
- On 30 September 2025, GSK plc began a £0.3 billion share buyback, part of its £2 billion program, to return capital to shareholders and boost earnings per share.1
- Intron Health upgraded GSK from 'sell' to 'buy' and raised the target price from 12 to 17 pounds, citing new product launches, better cost control, and improved R&D strategy.2
- GSK's CEO Emma Walmsley will resign at year-end, with insider Luke Miels taking over, as the firm aims to boost its pipeline and tackle U.S. trade tariff uncertainties.3